Myriad Genetics Inc.

# Signal Note: Deerfield Management Initiates MYRIAD Position Deerfield's modest $3K entry into MYRIAD suggests conviction in the company's core genomic diagnostics franchise rather than a near-term catalyst play. The position sizing indicates either a pilot position ahead of potential pipeline developments (notably their ovarian cancer risk assessment tools) or opportunistic buying at depressed valuations, though no imminent catalyst is apparent from public filings.